GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

cusatuzumab   Click here for help

GtoPdb Ligand ID: 9778

Synonyms: ARGX-110 | ARGX110 | clone 41D12
Immunopharmacology Ligand
Compound class: Antibody
Comment: Cusatuzumab (ARGX-110) is a highly potent, afucosylated, humanized IgG1 anti-CD70 antibody being investigated for potential against solid and hematological tumours [2].
No information available.
Summary of Clinical Use Click here for help
ARGX-110 is in clinical trials for various cancers; Max Phase 2. Click here to view ClinicalTrials.gov's list of registered ARGX-110 trials.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04241549 A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment Phase 1 Interventional Janssen Pharmaceutical K.K.